Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Vipoma 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Solid Tumors 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Insulinoma 1Glucagonoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Gastrinoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Breast Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Temozolomide 6Capecitabine 4Everolimus 3Thalidomide 2Sunitinib 2Streptozocin 2Octreotide 2Injections 2Fluorouracil 2surufatinib 1sargramostim 1recombinant interferon alpha 2b-like protein 1nimotuzumab 1motesanib diphosphate 1montanide ISA 51 1lutetium Lu 177 dotatate 1incomplete Freund's adjuvant 1ibrutinib 1ganitumab 1cabozantinib 1belzutifan 1batifiban 1atezolizumab 1abemaciclib 1Tegafur 1Specimen Handling 1PM 01183 1Metformin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenoma, Islet Cell × motesanib diphosphate × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡